CSIMarket
 
Processa Pharmaceuticals Inc   (PCSA)
 

Processa Pharmaceuticals Inc released operating deficit of $-6.057118 million, in the third quarter of 2022 financial report

PCSA recorded third quarter of 2022 operating deficit of $-6.057118 million


Published Nov 28 2022
CSIMarket Team / CSIMarket.com


Dryvax_pd Following the large companies in the Major Pharmaceutical Preparations industry, some overlooked entities are publishing the earnings. PCSA mentioned it has clinched operating deficit of $-6.057118 million, for the third quarter of 2022.

The operating deficit has depleted from $-3.459797 million, from the third quarter of 2021. But more importantly, the market observers are speculating, when the PCSAs' could begin to cite the revenue.


It is not really a surprise, that the small company recorded a net loss of $-6.020 million, that has widen from $-3.157 million, in third quarter of 2021.


Processa Pharmaceuticals Inc is expected to report next financial results on May 01, 2023.



Processa Pharmaceuticals Inc's Operating Margin

Processa Pharmaceuticals Inc's Price to sales ratio PS



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com